Caldera dei Campi Flegrei: potenzialità di un SIT per valutazioni di pericolosità vulcanica

La caldera dei Campi Flegrei è un’area vulcanica attiva, attualmente in stato di quiescenza dal 1538 d.C., soggetta ad un elevato rischio vulcanico per la presenza di numerosi centri abitati e per l’immediata vicinanza alla città di Napoli. Le due maggiori eruzioni esplosive dei Campi Flegrei risalgono a circa 39 ka e 15 ka ed hanno prodotto l’Ignimbrite Campana ed il Tufo Giallo Napoletano, i depositi più noti dell’area napoletana, distribuiti su aree vastissime. Al presente, il sistema magmatico risulta essere ancora attivo, come testimoniato dall’eruzione di Monte Nuovo nel 1538, dai recenti episodi bradisismici e dall’attività fumarolica e idrotermale. Al fine di rendere disponibile alla comunità scientifica ed agli enti preposti alla gestione delle emergenze un efficace strumento tecnologico, a supporto delle valutazioni di pericolosità vulcanica, è stato implementato un sistema informativo territoriale strutturato sulla base di un database in cui sono state raccolte e organizzate tutte le informazioni vulcanologiche e territoriali sull’area. In questo lavoro, attingendo al patrimonio informativo disponibile, sono state effettuate analisi di dettaglio finalizzate alla produzione di nuovi tematismi da utilizzare per la definizione degli scenari di evento, attraverso i quali simulare le conseguenze di un evento vulcanico, di caratteristiche prefissate, che si verifichi nell’area dei Campi Flegrei

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis. a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method: This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. Results: The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study. Conclusion: Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials

Central venous catheterization: complications of different placements

Abstract STUDY AIM: The aim of this prospective multicentric non-randomised trial was to report the complications of the central venous catheter insertion with different techniques and to assess the advantages of the low lateral approach to the internal jugular vein, according to the technique originally described by Jernigan et al, with our own modifications. PATIENTS AND METHOD: From January 1993 to August 1997, 2,290 CVC (2,286 by percutaneous puncture and 4 by surgical approach) were placed. The following complications were analysed prospectively: pneumothorax, accidental arterial puncture, more than two punctures of the same vein, necessity to shift to another venous approach, complete failure, malposition of catheter. RESULTS: The veins the most frequently used were internal jugular vein (48.7%), femoral vein (27%) and subclavian vein (24.2%). Internal jugular vein was punctured especially by low lateral approach (75%) and subclavian vein by infraclavicular approach (92%). With these two placements, the rate of pneumothorax was 0% and 3.1% respectively (p < 0.001), the rate of accidental arterial puncture was 1% and 2.7% respectively (p < 0.03) and the rate of more than two consecutive punctures was 3.1% and 6.3% respectively (p < 0.008). CONCLUSION: On our experience, we advocate the low lateral approach to the internal jugular vein as first choice technique for venipuncture in both adults and children for both short and long-term central venous approach, because it is associated to high rate of outcome and to low rate of complications in comparison with other techniques

Caldera dei Campi Flegrei: potenzialità di un SIT per valutazioni di pericolosità vulcanica

La caldera dei Campi Flegrei è un’area vulcanica attiva, attualmente in stato di quiescenza dal 1538 d.C., soggetta ad un elevato rischio vulcanico per la presenza di numerosi centri abitati e per l’immediata vicinanza alla città di Napoli. Le due maggiori eruzioni esplosive dei Campi Flegrei risalgono a circa 39 ka e 15 ka ed hanno prodotto l’Ignimbrite Campana ed il Tufo Giallo Napoletano, i depositi più noti dell’area napoletana, distribuiti su aree vastissime. Al presente, il sistema magmatico risulta essere ancora attivo, come testimoniato dall’eruzione di Monte Nuovo nel 1538, dai recenti episodi bradisismici e dall’attività fumarolica e idrotermale. Al fine di rendere disponibile alla comunità scientifica ed agli enti preposti alla gestione delle emergenze un efficace strumento tecnologico, a supporto delle valutazioni di pericolosità vulcanica, è stato implementato un sistema informativo territoriale strutturato sulla base di un database in cui sono state raccolte e organizzate tutte le informazioni vulcanologiche e territoriali sull’area. In questo lavoro, attingendo al patrimonio informativo disponibile, sono state effettuate analisi di dettaglio finalizzate alla produzione di nuovi tematismi da utilizzare per la definizione degli scenari di evento, attraverso i quali simulare le conseguenze di un evento vulcanico, di caratteristiche prefissate, che si verifichi nell’area dei Campi Flegrei.PublishedL'Aquila - Italy5.4. TTC - Sistema Informativo Territorialeope

Application of proteomics and metabolomics to study inherited kidney disorders: from big data to precision medicine

The recent application of proteomics and metabolomics to clinical medicine has demonstrated their potential role in complementing genomics for a better understanding of diseases' patho-physiology. These technologies offer the clear opportunity to identify risk factors, disease-specific or stage-specific biomarkers and to predict therapeutic response. This article is an overview of the recent insights obtained by metabolomic and proteomic studies in inherited kidney disorders. Proteomics studies have allowed the definition of a detailed picture of protein composition, post-translational modifications and interactions in kidney-derived samples, improving our understanding of renal physiology, especially of tubular transport and primary cilium-related functions. Studies on patients' urine samples and experimental models of inherited kidney diseases have provided clues suggesting novel potential pathological mechanisms and biomarkers of disease, for example in polycystic kidney disease. Metabolomic-based studies have been recently applied to assess biological system disturbances caused by specific genetic mutations resulting in inherited kidney disorders. These studies have been mainly carried out on mouse and rat models of cystic and metabolic disorders (such as Fabry disease), and on patients' urine samples. They have provided a significant contribution in understanding disease pathophysiology, promoting the discovery of aberrant biochemical pathways and contributing to the development of targeted therapies